Get started
Author

Shiqing Chen

Observed names: Shi-Qing Chen, Shi-qing Chen
Observed institutions: Malaysian Palm Oil Board, Shanghai Jiao Tong University, Anhui Medical University, Chinese Academy of Sciences, Shanghai Mental Health Center, Zhuhai People's Hospital, Shanghai Institutes for Biological Sciences, The First People's Hospital of Jiangxia District, State Key Laboratory of Analytical Chemistry for Life Science, 3D Medicines, Inc. (China), Shanghai Key Laboratory of Psychotic Disorders, Huazhong University of Science and Technology, Southwest Jiaotong University, Nanjing Medical University, Chongqing Medical University, Nanjing University
ORCID: 0000-0002-7544-9916
Observed ORCID: 0000-0002-7544-9916
OpenAlex ID: A5088822063
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
2019 · Jianchun Duan, Longgang Cui, et al. · JAMA Oncology · 355
PDF
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
2023 · Wenwen Zhang, Shuang Tong, et al. · Journal for ImmunoTherapy of Cancer · 145
PDF
A pilot study of neoadjuvant combination of anti-PD-1 camrelizumab and VEGFR2 inhibitor apatinib for locally advanced resectable oral squamous cell carcinoma
2022 · Wu-tong Ju, Rong-hui Xia, et al. · Nature Communications · 144
PDF
Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
2022 · Zhengbo Song, Yuping Li, et al. · BMC Medicine · 72
PDF
Genomic alterations in biliary tract cancer predict prognosis and immunotherapy outcomes
2021 · Xiaofeng Chen, Deqiang Wang, et al. · Journal for ImmunoTherapy of Cancer · 64
Characterization of the genomic landscape in large-scale Chinese patients with pancreatic cancer
2022 · Xiaofei Zhang, Tiebo Mao, et al. · EBioMedicine · 62
PDF
Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
2021 · Zhengbo Song, Dongqing Lv, et al. · Clinical Cancer Research · 54
PDF
The unique prognostic characteristics of tumor deposits in colorectal cancer patients
2019 · Fangqi Liu, Jiang Zhao, et al. · Annals of Translational Medicine · 54
PDF
Neoadjuvant sintilimab in combination with concurrent chemoradiotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: a single-arm phase 2 trial
2023 · Jia Wei, Xiaofeng Lu, et al. · Nature Communications · 53
PDF
First-line camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and chemotherapy for advanced gastric cancer (SPACE): a phase 1 study
2024 · Xiaofeng Chen, Hao Xu, et al. · Signal Transduction and Targeted Therapy · 51
PDF
PIK3CA mutations-mediated downregulation of circLHFPL2 inhibits colorectal cancer progression via upregulating PTEN
2022 · Xiaodan Chong, Jingde Chen, et al. · Molecular Cancer · 50
PDF
Confinement in Dual-Chain-Locked DNA Origami Nanocages Programs Marker-Responsive Delivery of CRISPR/Cas9 Ribonucleoproteins
2023 · Ziqi Xu, Yuxiang Dong, et al. · Journal of the American Chemical Society · 48
Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
2022 · Zhenghang Wang, Qi Zhang, et al. · Journal for ImmunoTherapy of Cancer · 43
PDF
LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma
2020 · Longrong Wang, Kai Yan, et al. · Journal of Cancer · 43
Regret-based cross efficiency evaluation method in a general two-stage DEA system
2022 · Qinxia Chen, Shiqing Chen, et al. · Computers & Industrial Engineering · 30
Potential “Therapeutic” Effects of Tocotrienol-Rich Fraction (TRF) and Carotene “Against” Bleomycin-Induced Pulmonary Fibrosis in Rats via TGF-β/Smad, PI3K/Akt/mTOR and NF-κB Signaling Pathways
2022 · Yifei Lu, Yihan Zhang, et al. · Nutrients · 28
PDF
Molecular Landscape of ERBB2 Alterations in 14,956 Solid Tumors
2022 · Hao Wang, Ji Miao, et al. · Pathology & Oncology Research · 22
Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With HER2 Alterations: A Multicenter Retrospective Study
2021 · Zhengbo Song, Dongqing Lv, et al. · Frontiers in Oncology · 21
PDF
Tumor microenvironment features decipher the outperformance of neoadjuvant immunochemotherapy over chemotherapy in resectable non-small cell lung cancer
2022 · Wenhan Cai, Miao Jing, et al. · Frontiers in Immunology · 19
Tumor immune microenvironment changes are associated with response to neoadjuvant chemotherapy and long-term survival benefits in advanced epithelial ovarian cancer: A pilot study
2023 · Guangming Cao, Dingchao Hua, et al. · Frontiers in Immunology · 18
PDF
Development and Validation of Postoperative Circulating Tumor DNA Combined with Clinicopathological Risk Factors for Recurrence Prediction in Patients with Stages I-III Colorectal Cancer
2022 · Zhaoya Gao, Dandan Huang, et al. · Journal of Translational Medicine · 18
PDF
Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer
2025 · Mei He, Congcong Ji, et al. · Gastric Cancer · 17
PDF
Vaccarin alleviates cisplatin-induced acute kidney injury via decreasing NOX4-derived ROS
2023 · Tingni Wu, Wenxian Ma, et al. · Heliyon · 17
Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
2022 · Zhengbo Song, Guangyuan Lou, et al. · BMC Medicine · 17
PDF
Landscape of FGF/FGFR Alterations in 12,372 Chinese Cancer Patients
2020 · Wei Zuo, Yan He, et al. · Journal of Cancer · 17
PDF
Works count: 105
Citation count: 1,787
H-index: 19
I10-index: 38
Year
Topic
Type